Table 2.
Authors | N= | Pre-OLT Duration* of LAM(mos) | HBV DNANegative at OLT(%) | HBIGRoute of Administration | HBV Reinfection(%) | Reference |
---|---|---|---|---|---|---|
Markowitz, et al. | 14 | 3 | 93 | IV | 0 | 43 |
Yao, et al. | 10 | 8.6 | 80 | IV then IM | 10 | 75 |
Yoshida, et al. | 7 | NR | 100 | IM | 0 | 80 |
Angus, et al. | 37 | 3.2 | NR | IM | 3 | 18 |
Marzano, et al. | 33 | 4.6 | 100 | IV | 4 | 15 |
McCaughan, et al. | 9 | 0 | NR | IM | 0 | 81 |
Rosenau, et al. | 21 | 4.6 | 77 | IV | 10 | 49 |
Roche, et al. | 15 | 4.6 | 73 | IV | 7 | 28 |
Han, et al. | 59 | NR | NR | IV | 0 | 14 |
Seehofer, et al. | 17 | 10.6 | 71 | IV | 18 | 48 |